Get the Stockscreener App
0.2111
3.17%
-0.0069
After Hours:
.21
-0.0011
-0.52%
Azitra Inc stock is traded at $0.2111, with a volume of 123.80K.
It is down -3.17% in the last 24 hours and down -14.29% over the past month.
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
See More
Previous Close:
$0.218
Open:
$0.2145
24h Volume:
123.80K
Relative Volume:
0.01
Market Cap:
$3.42M
Revenue:
$7,500
Net Income/Loss:
$-10.96M
P/E Ratio:
-0.092
EPS:
-2.2943
Net Cash Flow:
$-11.41M
1W Performance:
-8.22%
1M Performance:
-14.29%
6M Performance:
-41.78%
1Y Performance:
-23.10%
1-Day Range:
$0.2101
$0.2201
1-Week Range:
$0.2101
$0.235
52-Week Range:
$0.10
$1.40
Azitra Inc Stock (AZTR) Company Profile
Name
Azitra Inc
Sector
Industry
Phone
203 646 6446
Address
21 Business Park Drive, Branford
Compare AZTR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZTR
Azitra Inc
|
0.2111 | 3.53M | 7,500 | -10.96M | -11.41M | -2.2943 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Azitra Inc Stock (AZTR) Latest News
Azitra Adjourns 2026 Annual Meeting for Lack of Quorum - TipRanks
Azitra (AZTR) delays 2026 annual meeting after low shareholder turnout - Stock Titan
Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting - Star Local Media
[EFFECT] Azitra, Inc. SEC Filing - Stock Titan
AZTR Stock Chart | AZITRA INC (NYSEARCA:AZTR) - ChartMill
Azitra Inc (AZTR) Surges 12%: Small-Cap Biotech Breaks Above SupportHead and Shoulders - thelegaladvocate.com
Azitra Inc (AZTR) Surges 12%: Testing Key Resistance at $0.24Wyckoff Accumulation - The Legal Advocate
Azitra Adjusts 2026 Annual Shareholders Meeting Schedule - The Globe and Mail
Azitra to Adjourn and Reconvene 2026 Annual Meeting to Allow Additional Proxy Voting Time - Minichart
Azitra Inc (AZTR) Slides to $0.21: Navigating Key Support at $0.20Fibonacci Time Zone - The Legal Advocate
Azitra Inc (AZTR) Tests Support Level as Stock Declines SlightlyVolume Rate Change - The Legal Advocate
Azitra announces intention to adjourn annual meeting and reconvene annual meeting - marketscreener.com
Azitra to adjourn June 4 annual meeting; reconvene virtually June 15 to allow additional proxy mailing time - TradingView
Azitra (NYSE: AZTR) sets June 15 date to reconvene 2026 virtual annual meeting - Stock Titan
Proxy mailing delay pushes Azitra’s virtual shareholder meeting - Stock Titan
Azitra Inc Financial Disclosures & SEC Filings - TradingView
Azitra Inc (AZTR) Q1 2026 Earnings: Wider-Than-Expected Loss Amid Pre-Revenue StageProfit Recovery Report - Newser
AZTR Q1 2026 Earnings: Significant EPS Miss and Stock Decline Amid Pre-Revenue StageEarnings Preview - The Legal Advocate
AZTR Q1 2026 Earnings: Significant EPS Miss Amidst Early-Stage DevelopmentShort-Term Outlook - Newser
AZTR Q1 2026 Earnings: Massive EPS Miss Exceeds Expectations as Stock Declines Nearly 4%Dividend Increase Stocks - The Legal Advocate
Azitra (NYSE: AZTR) S-1 shows massive resale dilution and risks - Stock Titan
Azitra (AZTR) Stock: Down -1.58%, Support Test at $0.18 2026-05-19Free Stock Community - Newser
AZTR SEC FilingsAzitra Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Azitra (AZTR) Stock Analysis: Falls -2.40%, Watching $0.20 2026-05-14Profit Surge - newser.com
Azitra 1Q Loss/Shr 25c >AZTR - Moomoo
Branford biotech Azitra expands into consumer skin-care market - Hartford Business Journal
Azitra, Inc. Q1 2024 Financial Report: Operating Expenses, Net Loss, and Key Disclosures - Minichart
Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates - PR Newswire
Azitra, Inc. Announces Q1 2026 Financial Results and Pipeline Milestones for Biotherapeutics and Cosmeceuticals - Minichart
Azitra (NYSE: AZTR) widens Q1 loss but lifts cash and equity via new financings - Stock Titan
Azitra reports Q1 2026 net loss $3.9M, cash $10.1M; advances ATR-12, ATR-04 trials - TradingView
Azitra, Inc. 1Q 2026: Net loss $(3.93M), EPS $(0.25) — 10-Q Summary - TradingView
Azitra, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Azitra (NYSE: AZTR) widens Q1 2026 loss but strengthens cash and pipeline - Stock Titan
MSN Money - MSN
Number of shareholders of Azitra Inc – AMEX:AZTR - TradingView
Azitra (NYSE American: AZTR) seeks OK for big share increase and reverse split - Stock Titan
[ARS] Azitra, Inc. SEC Filing - Stock Titan
Azitra granted new U.S. patent protecting ATR-12 program - TipRanks
Azitra receives U.S. patent for Netherton syndrome treatment - Investing.com UK
Azitra receives U.S. patent for Netherton syndrome treatment By Investing.com - Investing.com Australia
Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program - PR Newswire
New U.S. patent covers trial therapy for a rare skin disease with no approved drugs - Stock Titan
Azitra Inc Stock (AZTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
3.22%
Cap:
|
Volume (24h):